Oral anticoagulant switching in patients with atrial fibrillation: a scoping review
Introduction Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF).
Several factors may cause OAC switching. Objectives To examine the phenomenon of OAC …
Several factors may cause OAC switching. Objectives To examine the phenomenon of OAC …
Many good reasons to switch from vitamin k antagonists to non-vitamin k antagonists in patients with non-valvular atrial fibrillation
GL Botto, P Ameri, R De Caterina - Journal of Clinical Medicine, 2021 - mdpi.com
Non-vitamin K oral anticoagulants (NOACs) are the first choice for prophylaxis of
cardioembolism in patients with non-valvular atrial fibrillation (AF) who are anticoagulant …
cardioembolism in patients with non-valvular atrial fibrillation (AF) who are anticoagulant …
Oral anticoagulant adherence and switching in patients with atrial fibrillation: a prospective observational study
Background Adherence to oral anticoagulants (OACs) in patients with atrial fibrillation (AF) is
important in preventing stroke. The dominance of retrospective studies using administrative …
important in preventing stroke. The dominance of retrospective studies using administrative …
Patient concern regarding bleeding side effects from oral anticoagulation therapy for atrial fibrillation: an analysis from the multicentre KiCS-AF registry
Aims The purpose of this study is to utilize patient-reported outcomes to determine the
percentage of patients concerned about mild to moderate bleeding side effects of …
percentage of patients concerned about mild to moderate bleeding side effects of …
Efficacy of low-dose versus traditional buprenorphine induction in the hospital: a quantitative and qualitative study
N Sulakvelidze, C Ronan, AF Peterkin… - American Journal of …, 2023 - journals.lww.com
Background: Emerging evidence suggests low-dose buprenorphine (LDB) induction can
expand opportunities for buprenorphine induction in patients who are taking taking …
expand opportunities for buprenorphine induction in patients who are taking taking …
Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis …
J Bergler-Klein, N Gotcheva, O Kalējs… - American Journal of …, 2024 - journals.lww.com
Background: Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with
Atrial Fibrillation (GLORIA-AF) is a prospective registry of outcomes from patients with newly …
Atrial Fibrillation (GLORIA-AF) is a prospective registry of outcomes from patients with newly …
Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of …
YS Lee, YS Oh, EK Choi, AKC Chern, P Jiampo… - Open …, 2021 - openheart.bmj.com
Purpose Dabigatran is a direct thrombin inhibitor approved for stroke prophylaxis in patients
with non-valvular atrial fibrillation (NVAF). Real-world data about patient preference …
with non-valvular atrial fibrillation (NVAF). Real-world data about patient preference …
Adesão ao tratamento e qualidade de vida em pacientes com fibrilação atrial não valvar em uso de anticoagulante oral direto versus antagonista de vitamina K …
V Zortéa - 2021 - lume.ufrgs.br
Introdução: Apesar da baixa prevalência, a fibrilação atrial (FA) é um fator de risco
importante para acidente vascular cerebral e provoca impacto econômico importante. Os …
importante para acidente vascular cerebral e provoca impacto econômico importante. Os …